Current Opinion in the Treatment of Diabetic Nephropathy
DOI:
https://doi.org/10.17140/NPOJ-1-104Keywords:
Diabetic nephropathy; Autophagy; MicroRNA; Chronic inflammation; Nlrp3; mTOR; AMPK and Sirt1.Abstract
Diabetic nephropathy is a leading cause of end-stage renal failure. Approximately
20-40% patients with diabetes mellitus will develop nephropathy with a significant proportion requiring regular dialysis or kidney transplantation. The International Diabetes Federation
estimates that 366 million people had diabetes worldwide in 2011 and 552 million people will
have this disease by 2030.1
The increasing incidence of diabetes elevates diabetic nephropathy
to one of the most important current public health issues, representing a significant burden on
the health system.2
Despite current interventional strategies being intensively implemented,
the number of patients with diabetes requiring renal replacement therapy for end-stage renal
disease is growing.3
Current treatments of diabetic nephropathy slow its progression,3
so the
optimal therapeutic strategy to arrest or reverse the nephropathy is needed urgently. As multiple
risk factors and their interactions promote the development of diabetic nephropathy, targeting
a single factor may be ineffective in the treatment of this disease; thus, optimal treatments by
targeting multiple factors need to be developed to arrest or reverse the diabetic nephropathy
References
Nickerson HD, Dutta S. Diabetic complications: current chal-lenges and opportunities. J Cardiovasc Transl Res. 2012; 5: 375- 379. doi: 10.1007/s12265-012-9388-1
Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013; 382: 260-272. doi: 10.1016/S0140-6736(13)60687-X
Lim A. Diabetic nephropathy-complications and treatment. International journal of nephrology and renovascular disease. 2014; 7: 361-381. doi: 10.2147/IJNRD.S40172
Tervaert TW, Mooyaart AL, Amann K, et al. Pathologic clas-sification of diabetic nephropathy. J Am Soc Nephrol. 2010; 21: 556-563. doi: 10.1681/ASN.2010010010
Mora-Fernandez C, Dominguez-Pimentel V, de Fuentes MM, et al. Diabetic kidney disease: from physiology to thera-peutics. J Physiol. 2014; 592: 3997-4012. doi: 10.1113/jphysi-ol.2014.272328
Badal SS, Danesh FR. New insights into molecular mecha-nisms of diabetic kidney disease. Am J Kidney Dis. 2014; 63: S63-S83. doi: 10.1053/j.ajkd.2013.10.047
Forbes JM, Cooper ME. Mechanisms of diabetic complica-tions. Physiological reviews. 2013; 93: 137-188. doi: 10.1152/ physrev.00045.2011
Chan GC, Tang SC. Diabetic nephropathy: landmark clini-cal trials and tribulations. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association-European Renal Association. 2015. doi: 10.1093/ ndt/gfu411
Fineberg D, Jandeleit-Dahm KA, Cooper ME. Diabetic ne-phropathy: diagnosis and treatment. Nature reviews. Endocri-nology. 2013; 9: 713-723.
Meng XM, Nikolic-Paterson DJ, Lan HY. Inflammatory pro-cesses in renal fibrosis. Nature reviews. Nephrology. 2014; 10: 493-503. doi:10.1038/nrneph.2014.114
Wada J, Makino H. Inflammation and the pathogenesis of diabetic nephropathy. Clinical science. 2013; 124: 139-152. doi: 10.1042/CS20120198
Gomez IG, Grafals M, Portilla D, Duffield JS. MicroRNAs as potential therapeutic targets in kidney disease. Journal of the Formosan Medical Association=Taiwan yi zhi. 2013; 112: 237- 243. doi: 10.1016/j.jfma.2012.12.011
Li R, Chung AC, Yu X, Lan HY. MicroRNAs in Diabetic Kidney Disease. International journal of endocrinology. 2014; 2014: 593956. doi: 10.1155/2014/593956
Khella HW, Bakhet M, Lichner Z, et al. MicroRNAs in kid-ney disease: an emerging understanding. Am J Kidney Dis. 2013; 61: 798-808. doi: 10.1053/j.ajkd.2012.09.018
Schena FP, Serino G, Sallustio F. MicroRNAs in kidney dis-eases: new promising biomarkers for diagnosis and monitoring. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2014; 29: 755-763. doi: 10.1093/ndt/gft223
Srivastava SP, Koya D, Kanasaki K. MicroRNAs in kid-ney fibrosis and diabetic nephropathy: roles on EMT and End-MT. BioMed research international. 2013; 2013: 125469. doi: 10.1155/2013/125469
Tanaka Y, Kume S, Kitada M, et al. Autophagy as a thera-peutic target in diabetic nephropathy. Experimental diabetes re-search. 2012; 2012: 628978. doi: 10.1155/2012/628978
Fang L, Zhou Y, Cao H, et al. Autophagy attenuates diabetic glomerular damage through protection of hyperglycemia-in-duced podocyte injury. PloS one. 2013; 8: e60546. doi: 10.1371/ journal.pone.0060546
Ding Y, Choi ME. Autophagy in diabetic nephropathy. The Journal of endocrinology. 2015; 224: R15-R30. doi: 10.1530/ JOE-14-0437
Wang Z, Choi ME. Autophagy in kidney health and dis-ease. Antioxid Redox Signal. 2014; 20: 519-537. doi: 10.1089/ ars.2013.5363
Kume S, Yamahara K, Yasuda M, et al. Autophagy: Emerging Therapeutic Target for Diabetic Nephropathy. Semin Nephrol. 2014; 34: 9-16. doi: 10.1016/j.semnephrol.2013.11.003
Kelly KJ, Liu Y, Zhang J, et al. Comprehensive genomic profiling in diabetic nephropathy reveals the predominance of proinflammatory pathways. Physiological genomics. 2013; 45: 710-719. doi: 10.1152/physiolgenomics.00028.2013
Lim AK, Tesch GH. Inflammation in diabetic nephropa-thy. Mediators of inflammation. 2012; 2012: 146154. doi: 10.1155/2012/146154
Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nature reviews. Immunology. 2013; 13: 397- 411. doi: 10.1038/nri3452
Baroja-Mazo A, Martin-Sanchez F, Gomez AI, et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nature immunology. 2014; 15: 738-748. doi: 10.1038/ni.2919
Ozaki E, Campbell M, Doyle SL. Targeting the NLRP3 in-flammasome in chronic inflammatory diseases: current perspec-tives. Journal of inflammation research. 2015; 8: 15-27. doi: 10.2147/JIR.S51250
Vilaysane A, Chun J, Seamone ME, et al. The NLRP3 in-flammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol. 2010; 21: 1732-1744.
Shahzad K, Bock F, Dong W, et al. Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic ne-phropathy. Kidney Int. 2015; 87: 74-84.
Chang A, Ko K, Clark MR. The emerging role of the in-flammasome in kidney diseases. Current opinion in nephrol-ogy and hypertension. 2014; 23: 204-210. doi: 10.1097/01. mnh.0000444814.49755.90
McClelland AD, Kantharidis P. microRNA in the develop-ment of diabetic complications. Clinical science. 2014; 126: 95- 110. doi: 10.1042/CS20130079
Wu H, Kong L, Zhou S, et al. The role of microRNAs in diabetic nephropathy. Journal of diabetes research. 2014; 2014: 920134. doi: 10.1155/2014/920134
Putta S, Lanting L, Sun G, et al. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol. 2012; 23: 458-469. doi: 10.1681/ASN.2011050485
Wang B, Komers R, Carew R, et al. Suppression of microR-NA-29 Expression by TGF-beta1 Promotes Collagen Expres-sion and Renal Fibrosis. J Am Soc Nephrol. 2012; 23: 252-265. doi: 10.1681/ASN.2011010055
Wang B, Koh P, Winbanks C, et al. miR-200a Prevents Renal Fibrogenesis Through Repression of TGF-{beta}2 Expression. Diabetes. 2011; 60: 280-287. doi: 10.2337/db10-0892
Zhong X, Chung AC, Chen HY, et al. miR-21 is a key thera-peutic target for renal injury in a mouse model of type 2 diabe-tes. Diabetologia. 2013; 56: 663-674. doi: 10.1007/s00125-012- 2804-x
Wang JY, Gao YB, Zhang N, et al. miR-21 overexpression enhances TGF-beta1-induced epithelial-to-mesenchymal transi-tion by target smad7 and aggravates renal damage in diabetic nephropathy. Molecular and cellular endocrinology. 2014; 392: 163-172. doi: 10.1016/j.mce.2014.05.018
Lai JY, Luo J, O’Connor C, et al. MicroRNA-21 in Glomeru-lar Injury. J Am Soc Nephrol. 2015; 26: 805-816. doi: 10.1681/ ASN.2013121274
Krupa A, Jenkins R, Luo DD, et al. Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy. J Am Soc Nephrol. 2010; 21: 438-447. doi: 10.1681/ASN.2009050530
Lieberthal W, Levine JS. The role of the mammalian target of rapamycin (mTOR) in renal disease. J Am Soc Nephrol. 2009; 20: 2493-2502. doi: 10.1681/ASN.2008111186
Kitada M, Kume S, Takeda-Watanabe A, et al. Sirtuins and renal diseases: relationship with aging and diabetic nephropathy. Clinical science. 2013; 124: 153-164. doi: 10.1042/CS20120190
Kroemer G, Marino G, Levine B. Autophagy and the inte-grated stress response. Molecular cell. 2010; 40: 280-293. doi: 10.1016/j.molcel.2010.09.023
Zhan M, Brooks C, Liu F, et al. Mitochondrial dynamics: regulatory mechanisms and emerging role in renal pathophysiol-ogy. Kidney Int. 2013; 83: 568-581.
Lee J, Giordano S, Zhang J. Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling. Biochem J. 2012; 441: 523-540. doi: 10.1042/BJ20111451
Ashrafi G, Schwarz TL. The pathways of mitophagy for quality control and clearance of mitochondria. Cell death and differentiation. 2013; 20: 31-42. doi: 10.1038/cdd.2012.81
Sharma K, Karl B, Mathew AV, et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney dis-ease. J Am Soc Nephrol. 2013; 24: 1901-1912. doi: 10.1681/ ASN.2013020126
Higgins GC, Coughlan MT. Mitochondrial dysfunction and mitophagy: the beginning and end to diabetic nephropathy? British journal of pharmacology. 2014; 171: 1917-1942. doi: 10.1111/bph.12503
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Nephrology (NOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.